Current Report Filing (8-k)

Date : 12/10/2018 @ 2:02PM
Source : Edgar (US Regulatory)
Stock : Phoenix Life Sciences International Ltd. (PLSI)
Quote : 0.1  0.0 (0.00%) @ 9:33PM

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15( d )

of the Securities Exchange Act

 

November 28, 2018

Date of Report (Date of Earliest Event Reported)

 

Phoenix Life Sciences International Limited.

(Exact name of registrant as specified in its charter)

 

Nevada   333-167275   46-0525378
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification Number)
         

3000 Lawrence Street

Denver, CO 80205

1.720.699.7222 or Investor Relations +1.888.717.5655

 (Address, including zip code, and telephone number, including area code,

of registrant's principal executive offices) 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐    Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐ 

 

 

   
 

 

PHOENIX LIFE SCIENCE INTERNATIONAL LIMITED

Form 8-K

Current Report

 

 

ITEM 7.01 REGULATION FD DISCLOSURE

 

On November 28, 2018, the Company’s Board of Directors announced that Angus Stewart has joined the company as the Agriculture and Horticulture Senior Advisor. Mr. Stewart has over two decades of experience specializing in horticulture and is currently an Agricultural and Horticultural Scientist and Consultant Plant Breeder of approximately 100 commercially released plant cultivars. He is an Honorary Research Associate at the University of Tasmania and has been involved in multiple significant studies including several on the benefits of cannabidiol (CBD). Additionally, Stewart has extensive experience with plant breeding techniques of all levels and is well versed in the best practices for the production and extraction of botanical active ingredients like cannabinoids. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 and the exhibit attached hereto are furnished to, but not filed with, the Securities and Exchange Commission.

 

On December 6, 2018, the Company’s Board of Directors announced that the Company has released an online version of its Investor Relations deck with an accompanying video presentation on its website and at  http://phxlife.net/PLSI-Deck . The deck and presentation walks prospective investors through the company’s background, overall mission, business model, future plans and information on how to invest in Phoenix Life’s goal of transforming the future of global healthcare. A copy of the press release is attached hereto as Exhibit 99.2. The information in this Item 7.01 and the exhibit attached hereto are furnished to, but not filed with, the Securities and Exchange Commission.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

 

 

(d)        

Exhibits. 

 

Exhibit  
Number Description of Exhibit
99.1 Press Release issued November 28, 2018.
99.2 Press Release issued December 6, 2018.

 

 

2  
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       
 

Phoenix Life Science International Limited

  

Date: December 7, 2018 By:   /s/ Martin Tindall  
    Martin Tindall
    Chief Executive Officer

 

 

3  

Phoenix Life Sciences (USOTC:PLSI)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Phoenix Life Sciences Charts.

Phoenix Life Sciences (USOTC:PLSI)
Intraday Stock Chart

Today : Saturday 16 November 2019

Click Here for more Phoenix Life Sciences Charts.

Latest PLSI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.